ÉèΪÊ×Ò³ ¼ÓÈëÊÕ²Ø

TOP

IMMUCYST 81mg£¨¿¨½éÃçÃâÒßÖÎÁƼÁ ¥¤¥à¥·¥¹¥È°ò×¢Óã©
Ò©µê¹ú±ð£º  
²úµØ¹ú¼Ò£º ÈÕ±¾ 
´¦ ·½ Ò©£º ÊÇ 
ËùÊôÀà±ð£º 81ºÁ¿Ë£¨3ºÁÉý£©/Æ¿ 
°ü×°¹æ¸ñ£º 81ºÁ¿Ë£¨3ºÁÉý£©/Æ¿ 
¼Æ¼Ûµ¥Î»£º Æ¿ 
Éú²ú³§¼ÒÖÐÎIJο¼ÒëÃû:
Èüŵ·ÆÓÐÏÞ¹«Ë¾
Éú²ú³§¼ÒÓ¢ÎÄÃû:
Sanofi Co.Ltd.
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·1:
http://www.info.pmda.go.jp/go/pack/6391701X1030_3_02/
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·2:
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·3:
Ô­²úµØÓ¢ÎÄÉÌÆ·Ãû:
IMMUCYST£¨¥¤¥à¥·¥¹¥È°ò×¢Óã©81mg£¨3mL£©/via
Ô­²úµØÓ¢ÎÄÒ©Æ·Ãû:
Bacillus of Calmette and Guerin£¨BCG)・Connaught strain
ÖÐÎIJο¼ÉÌÆ·ÒëÃû:
IMMUCYST¹à×¢£¨¥¤¥à¥·¥¹¥È°ò×¢Óã©81ºÁ¿Ë£¨3ºÁÉý£©/Æ¿
ÖÐÎIJο¼Ò©Æ·ÒëÃû:
¿¨½éÃçÃâÒßÖÎÁƼÁ
ÔøÓÃÃû:
¼ò½é£º

 

²¿·ÝÖÐÎÄ¿¨½éÃçÃâÒßÖÎÁƼÁ´¦·½×ÊÁÏ£¨½ö¹©²Î¿¼£©
ЧÂÊ·ÖÀàÃû³Æ
ÆäËûÉúÎïÖÆÆ·
¿¹Ö×ÁöÒ©Îï
Åú×¼ÈÕÆÚ£º2003Äê10ÔÂ
É̘ËÃû
IMMUCYST
Ò»°ãÃû
BCG・¥³¥ó¥Î©`¥ÈÖê
Bacillus of Calmette and Guerin£¨BCG)・Connaught strain
ÐÔ¡¡×´
ËüÊÇÒ»ÖÖ¼õ¶¾µÄÅ£½áºË¸Ë¾ú½áºË·ÖÖ¦¸Ë¾ú»î¾ú£¬ËüÊÇÒ»ÖÖËáÐԸ˾ú£¬ÏÔʾ³ö´úÂëÐγɡ£
ÉóÅúÌõ¼þ
ΪÁ˽øÒ»²½²ûÃ÷¸ÃÒ©ÔÚ¹úÄÚµÄÓÐЧÐԺͰ²È«ÐÔ£¬ÔÚÈÕ±¾½øÐÐÊʵ±µÄÉÏÊкóÁÙ´²ÊÔÑé
ҩЧҩÀí
1. ¿¹Ö×Áö×÷ÓÃ
(1) ͨ¹ý½«Ð¡Êó°òë×ÒÆÐÐϸ°û°©Ï¸°ûϵMB49»òMBT-2Óë¸ÃÒ©Îï»ìºÏ²¢Æ¤ÏÂÒÆÖ²À´ÒÖÖÆÖ×ÁöÉú³¤ºÍÖ²Èë¡£
(2) ÔÚͨ¹ýÓÃÑÎËá´¦ÀíСÊóµÄ°òë×ÄÚ±ÚÖƱ¸µÄСÊó°òë×°©Ä£ÐÍÖй۲쵽´æ»îµÄÏÔ×ÅÑÓ³¤£¬²¢ÇÒÔÚ°©Ï¸°ûÖ²Èë°òë׺ó2Ì콫MB49ϸ°û×¢ÉäÈë°òëס£
2. ×÷ÓûúÐò
¾¡¹Ü×÷ÓõÄÃ÷È·»úÖÆÉÐδ²ûÃ÷£¬µ«ÊǸÃÒ©Îïͨ¹ýϸ°ûÍâ»ùÖʵ°°×ÏËÁ¬µ°°×µÄÕ³¸½1£©±»Ö×Áöϸ°û£¬¾ÞÊÉϸ°ûµÈÎüÊÕ²¢¼¤»îÃâÒß»îÐÔϸ°ûÈç¾ÞÊÉϸ°ûºÍTÁÜ°Íϸ°û Òª×ö¡£ ÕâЩ»î»¯µÄÃâÒß»îÐÔϸ°ûÖ±½ÓËðÉË°©Ï¸°û²¢·ÖÃÚ¿¹Ö×Áöϸ°ûÒò×Ó£¨Ö×Áö»µËÀÒò×Ó£¬¸ÉÈÅËØ-γµÈ£©²¢ÆÆ»µ°©Ï¸°û¡£
ÓÉÓÚ¸ÃÒ©Îï²»Ö±½Ó¶ÔÈË°òë×°©Ï¸°ûÏÔʾϸ°ûɱÉË×÷Óã¬ÍƲâÈçÉÏËùÊöÓÕµ¼ÃâÒß·´Ó¦ÏÔʾ¶Ô°òë×°©Ï¸°ûµÄ¿¹Ö×Áö×÷Óá£
ÊÊÓ¦²¡Ö¢
dz±íÐÔ°òë×°©£¬°òë×ÉÏƤÄÚ°©
Ó÷¨ÓëÓÃÁ¿
¼ÓÈë3ºÁÉýÁѽâÈÜÒº¸½¼Óµ½1Æ¿£¨81ºÁ¿Ë£©µÄ²úÆ·£¬ÖƳɾùÔȵÄÐü¸¡Òº£¬½øÒ»²½ÓÃ40ºÁÉýÈÕ±¾Ò©µäÑÎˮϡÊÍ£¬ÖƱ¸Ò»¸öͳһµÄ¿¨½éÃçÏ¡ÊÍÒº¡£
dz±íÐÔ°òë×°©£¬°òë×ÉÏƤÄÚ°©
½«ÄòµÀµ¼¹ÜÔÚÎÞ¾úÌõ¼þϲåÈë°òë×£¬ÔÚÅųö²ÐÓàÄòÒººó»ºÂý×¢ÈëBCGÏ¡ÊͼÁ£¬²¢¾¡¿ÉÄܽ«Æä±£³ÖÔÚ°òë×ÖÐ2Сʱ¡£ ͨ³£Ã¿ÖÜÖظ´Ò»´Î£¬³ÖÐø8ÖÜ¡£
dz±íÐÔ°òë×°©
½«ÄòµÀµ¼¹ÜÔÚÎÞ¾úÌõ¼þϲåÈë°òë×£¬ÔÚÅųö²ÐÓàÄòÒººó»ºÂý×¢ÈëBCGÏ¡ÊͼÁ£¬²¢¾¡¿ÉÄܽ«Æä±£³ÖÔÚ°òë×ÖÐ2Сʱ¡£ ÔÚ¾­ÄòµÀ°òë×Ö×ÁöÇгýÊõºóÖÁÉÙÁ¬Ðø14Ì죬ÿÖÜÒ»´Î£¬Á¬Ðø6ÖÜ£¬ÒÔ¼°Á¬Ðø3ÖÜ£¬6,12ºÍ18¸öÔ£¬´Ó¿ªÊ¼¸øÒ©¿ªÊ¼µÚ3,6,12ºÍ18¸öÔ£¬Ã¿ÖÜÒ»´Î£¬Á¬Ðø3ÖÜ¡£ ¸ù¾Ý²¡È˵ÄÇé¿ö£¬×ÃÇé¸øÒ©¡£
´æ´¢·½·¨·µ½ÆÚÈÕÆÚµÈ
±£´æ·½·¨
´¢´æÔÚ2〜8°C±Ü¹â
ÓÐЧÆÚÏÞ
×ÔÈÏÖ¤Ö®ÈÕÆðÁ½Ä꣨СƿºÍÍâÏäÉϵÄ×îºóÉúЧÈÕÆÚ£©
°ü×°¹æ¸ñ
81ºÁ¿Ë£º1Æ¿£¨¸½£º½âÒº£©
ÖÆÔìÉÌ
Èüŵ·ÆÓÐÏÞ¹«Ë¾
×¢£ºÒÔÉÏÖÐÎÄ×ÊÁϲ»¹»ÍêÕû£¬Ê¹ÓÃÕßÒÔÔ­´¦·½×ÊÁÏΪ׼¡£
ÍêÕû˵Ã÷Ê鸽¼þ£ºhttp://www.info.pmda.go.jp/go/pack/6391701X1030_3_02/
Adjustment and addition of dosage of adjuvant therapy after TURBT for superficial bladder cancer of imcyst® for bladder cancer
About additional indication of anti-malignant agent 'imsist® for bladder 81 mg'
On August 20, 2010, sanofi-aventis Co., Ltd. (Headquarters: Shinjuku-ku, Tokyo, President: Patrick Shoka, hereinafter "sanofi-aventis") and Nippon Kayaku Co., Ltd. (Headquarters: President and Chief Executive Officer, Chiyoda- : Nippon Kayaku, hereinafter referred to as "Nippon Kayaku") is an anti-cancer agent sold by sanofi-aventis "imsist® 81 mg for bladder" (generic name: dry BCG for intravesical (Connaught stock), manufacturing approval: Nippon Kayaku) announced today that we have received additional approval of dosage and dose at adjunctive therapy after transurethral bladder tumor resection (TURBT) in superficial bladder cancer.
Imsist®is an antineoplastic agent containing as active ingredient BCG·Connaught stock developed by the Connaught Institute of Canada (currently sanofi pasteur tool: vaccine business department of sanofi·aventis group). In Japan, in October 2002 Nippon Kayaku obtained manufacturing and marketing approval for the efficacy and efficacy of superficial bladder cancer and carcinoma in the bladder epithelium. After that, we conducted a clinical trial to add dosage and dose at adjuvant therapy after transurethral resection in superficial bladder cancer, and applied in April 2009. With this additional approval, ImSyst ® enables maintenance injection therapy in addition to BCG induction therapy for bladder cancer patients with high risk of recurrence.
ImSyst ® has been used for treatment of patients with superficial bladder cancer and bladder intraepithelial carcinoma since its release in 2003 in Japan. In addition, adjuvant therapy by imsist after TURBT has been approved in 52 countries around the world as an effective treatment for preventing the recurrence and development of bladder cancer. 

¡¾´ó ÖРС¡¿¡¾´òÓ¡¡¿ ¡¾·±Ìå¡¿¡¾Í¶¸å¡¿¡¾Êղء¿ ¡¾ÍƼö¡¿¡¾¾Ù±¨¡¿¡¾ÆÀÂÛ¡¿ ¡¾¹Ø±Õ¡¿ ¡¾·µ»Ø¶¥²¿¡¿
·ÖÏíµ½QQ¿Õ¼ä
·ÖÏíµ½: 
ÉÏһƪ£ºGemcitabine for I.V. Infusion 1.. ÏÂһƪ£ºJavlor 25mg/ml.Inf.1X2ML£¨vinfl..

Ïà¹ØÀ¸Ä¿

×îÐÂÎÄÕÂ

ͼƬÖ÷Ìâ

ÈÈÃÅÎÄÕÂ

ÍƼöÎÄÕÂ